San Diego, August 29, 2023–(BUSINESS WIRE)–Rezebio, Inc., a targeted radiopharmaceutical company developing an innovative pipeline against validated solid tumor targets, has appointed Christy Oliger to its Board of Directors. Ms. Oliger has more than 30 years of experience in the biopharmaceutical industry as a board member and executive, serving in various commercial and portfolio management roles at Genentech, Inc., Roche Holding AG and Schering-Plough Corporation.
“I am very excited about the impact Rezebio will have on cancer patients and the broader targeted radiopharmaceutical sector. I look forward to working with Rezebio’s accomplished management team in the next phase of the company’s growth,” said Ms. Oliger.
“I am pleased to welcome Christie to our Board of Directors. Christie brings extensive experience commercializing innovative products. She will be an invaluable resource to Rezebio as we move our lead into a Phase 3 clinical trial. Will continue to advance the clinical program.” Ken Song, MD, President and CEO of Rezebio.
During her career spanning more than 30 years, Ms. Oliger served as CEO of Genentech, Inc. from January 2000 until her retirement in July 2020. and Roche Holding AG and from September 1992 to December 1999 at Schering-Plough Corporation in various business roles. , Ms. Oliger filed a complaint against Genentech, Inc. Served as Senior Vice President, Oncology Business Unit Head. Genentech, Inc. During her tenure at the U.S., Ms. Oliger held senior leadership roles in various therapeutic areas including oncology, neurology, rare diseases. Respiratory, dermatology and immunology in hospital and specialized settings. He is currently managing director of Rita Pharmaceuticals, Inc., Replimune Group Inc., KarioPharm Therapeutics Inc. and Lava Therapeutics, each of which is a publicly traded pharmaceutical company. Previously, Ms. Oliger served as Sierra Oncology, Inc. He also served on the board of GSK, which was acquired by GSK for $1.9 billion. Ms. Oliger received her BA in Economics from the University of California at Santa Barbara.
About RayzeBio
RayzeBio is a biotechnology company focused on improving outcomes for people with cancer by harnessing the power of targeted radioisotopes. With a focus on clinically validated solid tumor targets, Rezebio is developing novel drug conjugates to provide a potent therapeutic radioisotope such as actinium-225, an alpha-emitter. Please visit www.rayzebio.com for additional information.
View source version on Businesswire.com: https://www.businesswire.com/news/home/20230829953305/en/
Contact
Arvind Kush
E-mail: [email protected]
Source
